What is claimed is:

Claim 1: A combination therapy comprising durvalumab and a platinum-based chemotherapy for use in treating resectable non-small cell lung cancer (R-NSCLC) in a patient in need thereof.

Claim 2: The combination therapy for use of claim 2, wherein the combination therapy is to be administered every 14 to 28 days for 3 to 6 cycles; optionally, wherein the combination therapy is to be administered about every 21 days (Q3W) for about 4 cycles.

Claim 3: The combination therapy for use of claim 2 further comprising resecting the R-NSCLC after the 3 to 6 cycles of the combination therapy; optionally, resecting the R-NSCLC after the about 4 cycles of the combination therapy.

Claim 4: The combination therapy for use of claim 3 wherein durvalumab is to be administered to the patient every 14 to 28 days for up to about twelve cycles after resecting the R-NSCLC; optionally, wherein durvalumab is to be administered to the patient about every 28 days (Q4W) for up to about twelve cycles after resecting the R-NSCLC.

Claim 5: The combination therapy for use of any one of claims 1-4, wherein the combination therapy comprises 1000 to 2000 mg of durvalumab; optionally, wherein the combination therapy comprises about 1500 mg of durvalumab.

Claim 6: A combination therapy for use in treating a patient identified as having resectable non-small cell lung carcinoma (R-NSCLC), wherein:

(i) about 1500 mg of durvalumab and a platinum-based chemotherapy is to be administered to the patient about every 3 weeks (Q3W) for about 4 cycles; and then
(ii) about 1500 mg of durvalumab is to be administered to the patient about every four weeks (Q4W) for at least about 12 weeks after removal of the R-NSCLC by surgery.

Claim 7: The combination therapy for use of any one of claims 1-6, wherein the platinum-based chemotherapy is one or more of carboplatin, cisplatin, nedaplatin, and oxaliplatin.

Claim 8: The combination therapy for use of any one of claims 1-7, wherein the R-NSCLC is a squamous cell carcinoma, or wherein the R-NSCLC is a non-squamous cell carcinoma.

Claim 9: The combination therapy for use of claim 8, wherein the platinum-based chemotherapy comprises:

(i) carboplatin and paclitaxel;

(ii) cisplatin and gemcitabine; and/or

(iii) carboplatin and gemcitabine.

Claim 10: The combination therapy for use of claim 9, wherein the R-NSCLC is a non-squamous cell carcinoma and wherein the platinum-based chemotherapy comprises:

(i) carboplatin and pemetrexed; and/or

(ii) cisplatin and pemetrexed.

Claim 11: The combination therapy for use of any one of claims 1-10, wherein the patient does not have an EGFR mutation and/or an ALK translocation.

Claim 12: The combination therapy for use of any one of claims 3-11, wherein resecting the R-NSCLC occurs within 10 weeks after the 3 to 6 cycles of the combination therapy.

Claim 13: The combination therapy for use of any one of claims 3-12 further comprising a post-operative radiation therapy, optionally wherein the post-operative radiation therapy starts within 8 weeks after resecting the R-NSCLC, optionally wherein durvalumab starts within 3 weeks from the end of the post-operative radiation therapy.

Claim 14: The combination therapy for use of any one of claims 1-13, wherein the use of the combination therapy results in one or more of:

(i) improvement in event-free survival (EFS) of at least 13 months;

(ii) improvement in pathological complete response (pCR) by at least 13%; and

(iii) improvement in major pathological response (mPR) by at least 21%.

Claim 15: The combination therapy for use of any one of claims 1-14, wherein the combination therapy for use results in improvement in one or more of EFS, pCR, mPR, DFS, and OS compared to a standard of care, and/or compared to a platinum-based chemotherapy.